Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB3 days ago · While on the whole, tolebrutinib was well-tolerated, there was a higher proportion of elevated liver enzymes with the drug compared to placebo, 4.1% versus 1.6%, which can indicate liver toxicity.
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB3 days ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Tolebrutinib Shows Positive Results in Slowing Disability …
WEB4 days ago · Newly announced late-breaking results from the phase 3 HERCULES trial (NCT04411641) showed that tolebrutinib (Sanofi), a Bruton’s tyrosine kinase (BTK) inhibitor, had a significant effect on disability accumulation compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). …
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2022 · New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis.
Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB3 days ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2017 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
Advancing BTK Inhibitor Research: Sanofi's Tolebrutinib Sets New …
WEBOct 13, 2007 · Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, tolebrutinib, demonstrated favorable one-year tolerability in a Phase 2b longterm extension study (LTS) in patients with relapsing forms of multiple sclerosis (RMS).
ECTRIMS 2023: Tolebrutinib show benefits for up to 3 years
WEBOct 16, 2023 · Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS),...
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK ...
WEB12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated.
Skip to content